Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 3 5Phase 1 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Pathologic Complete Response 1Neoplasm, Residual 1Metastatic Castration-Resistant Prostate Cancer 1Hormone Treatment-naïve Participants With Prostate Cancer 1Endometriosis 1Adenocarcinoma 1

Interventions

Docetaxel 43enzalutamide 31Prednisone 25Abiraterone Acetate 24Magnetic Resonance Spectroscopy 18abiraterone 15pembrolizumab 14bicalutamide 14Radiotherapy 14Cyclophosphamide 13darolutamide 12Leuprolide 12Goserelin 12apalutamide 10Ipilimumab 10olaparib 9Specimen Handling 9Radiosurgery 9Radiation 9Injections 9Biopsy 9Pluvicto 8Paclitaxel 8Radiotherapy, Intensity-Modulated 7Carboplatin 7sargramostim 6fludarabine 6cabazitaxel 6Sirolimus 6Nivolumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Prostatic Neoplasms × relugolix × Clear all
NCT06631521 2026-02-05

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

AdventHealth

Phase 1 Recruiting
30 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT05679388 2024-09-19

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

University of Chicago

Phase 1 Terminated
60 enrolled
Genitourinary

Prostatic Neoplasms

NCT02093390 2016-06-06

A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
40 enrolled 23 charts
Genitourinary

Endometriosis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡